TYRA · Company research
Tyra Biosciences, Inc. Common Stock (TYRA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Average Target Price of $47.20 According to Analysts - MarketBeat | Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Average Target Price of $47.20 According to Analysts MarketBeat | View source ↗ | MarketBeat | Oct 20, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences (NASDAQ:TYRA) Stock Jumps 4.4% - Here's Why - MarketBeat | Tyra Biosciences (NASDAQ:TYRA) Stock Jumps 4.4% - Here's Why MarketBeat | View source ↗ | MarketBeat | Oct 20, 2026 | neutral | 0 | 0.6 |
| TYRA 261120 30.00P (TYRA261120P30000) Stock Options Chain | Quotes & News - Moomoo | TYRA 261120 30.00P (TYRA261120P30000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 19, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance UK | Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 18, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History - Yahoo! Finance Canada | Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value - Yahoo Finance | Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value Yahoo Finance | View source ↗ | Yahoo Finance | Oct 17, 2026 | neutral | 0 | 0.6 |
| Avoiding Lag: Real-Time Signals in (TYRA) Movement - Stock Traders Daily | Avoiding Lag: Real-Time Signals in (TYRA) Movement Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 14, 2026 | neutral | 0 | 0.6 |
| Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks - Yahoo! Finance Canada | Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| Law firm probes Tyra Biosciences over possible securities fraud after drug trial safety concerns. - Pluang | Law firm probes Tyra Biosciences over possible securities fraud after drug trial safety concerns. Pluang | View source ↗ | Pluang | Oct 13, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA | Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 study results for dabogratinib. Despite claims of a favorable safety profile, the trial showed Grade 3 adverse events in 9-14% of participants, leading to a 17.66% stock price decline on September 9, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bearish | -1 | 1 |
| Tyra Biosciences, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq | Tyra Biosciences, Inc. Rings the Nasdaq Stock Market Opening Bell Nasdaq | View source ↗ | Nasdaq | Oct 13, 2026 | neutral | 0 | 0.6 |
| TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout - Stocktwits | TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences (TYRA) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | Tyra Biosciences (TYRA) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences faces investigation after adve... - Pluang | Tyra Biosciences faces investigation after adve... Pluang | View source ↗ | Pluang | Oct 8, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA | Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA | Pomerantz LLP is investigating potential securities fraud claims against Tyra Biosciences following the company's announcement of Phase 2 SURF302 study results for oral dabogratinib. Despite claims of a favorable safety profile, the study showed 14% and 9% of participants experienced Grade 3 adverse events in the 60mg and 50mg dose cohorts respectively. The announcement triggered a 17.66% stock price decline on September 9, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance Australia | Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history Yahoo Finance Australia | View source ↗ | Yahoo Finance Australia | Oct 2, 2026 | neutral | 0 | 0.6 |
| Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - PR Newswire | Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants PR Newswire | View source ↗ | PR Newswire | Sep 14, 2026 | neutral | 0 | 0.6 |
| Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP | Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants Latham & Watkins LLP | View source ↗ | Latham & Watkins LLP | Sep 14, 2026 | neutral | 0 | 0.6 |
| Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock - Fierce Biotech | Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock Fierce Biotech | View source ↗ | Fierce Biotech | Sep 9, 2026 | neutral | 0 | 0.6 |
| Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire | Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights PR Newswire | View source ↗ | PR Newswire | Aug 4, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.